Of these patients, 59 had an autoantibody result: 19 (32%) had anti-TIF1γ, 7 (12%) had anti-NXP2, 1 (2%) had anti-MDA5, 1 (2%) had anti-Mi2, 1 (2%) had anti-SRP, 1 (2%) had anti-PL-7 and 1 (2%) had anti-HMGCR myositis-specific autoantibodies. Here, IFIH1 is linked to myositis disease.